Literature DB >> 2196024

Asymptomatic bacteriuria. Which patients should be treated?

G G Zhanel1, G K Harding, D R Guay.   

Abstract

Asymptomatic bacteriuria is common in both the community nursing home and hospital settings. Few data, however, are available about the potential complications arising from asymptomatic bacteriuria (eg, the development of symptomatic infection and renal damage) for various patient populations and for various medical conditions. On the basis of data in the literature, we believe that neonates and preschool children with asymptomatic bacteriuria should be treated. Pregnant women and "nonelderly" (less than 60 years old) men should be treated. We do not think that school-age children, nonpregnant, nonelderly women, or elderly men and women need antimicrobial treatment if their urinary tracks are normal. In addition, antimicrobial treatment is recommended for patients with asymptomatic bacteriuria and abnormal urinary tracts and those undergoing clean intermittent catheterization, genitourinary manipulation, or instrumentation. Patients with long-term indwelling catheters should not be treated. The treatment of asymptomatic bacteriuria in patients with short-term indwelling catheters and those with ileal conduits is controversial. These treatment recommendations should not necessarily be accepted as the standards of practice, since treatment is often controversial due to the lack of published data describing the natural course of asymptomatic bacteriuria in various patient populations.

Entities:  

Mesh:

Year:  1990        PMID: 2196024     DOI: 10.1001/archinte.150.7.1389

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

Review 1.  Treatment of bacteriuria in pregnancy.

Authors:  J S Tan; T M File
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 2.  Catheter-associated infections: pathogenesis affects prevention.

Authors:  Barbara W Trautner; Rabih O Darouiche
Journal:  Arch Intern Med       Date:  2004-04-26

3.  A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI.

Authors:  J D McCue; P Gaziano; D Orders
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 4.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

5.  Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria.

Authors:  S Iftimie; A García-Heredia; I Pujol; F Ballester; I Fort-Gallifa; J M Simó; J Joven; J Camps; A Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-22       Impact factor: 3.267

Review 6.  Role of biofilm in catheter-associated urinary tract infection.

Authors:  Barbara W Trautner; Rabih O Darouiche
Journal:  Am J Infect Control       Date:  2004-05       Impact factor: 2.918

Review 7.  Management of bacterial urinary tract infections in adult patients with diabetes mellitus.

Authors:  Ruby Meiland; Suzanne E Geerlings; Andy I M Hoepelman
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Diagnostic regimes for urinary tract infection--are research results applied to practice?

Authors:  V L Crawford; B McPeake; R W Stout
Journal:  Ulster Med J       Date:  1995-10

9.  Prevalence, risk factors and microorganisms of urinary tract infections in patients with type 2 diabetes mellitus: a retrospective study in China.

Authors:  Ke He; Yun Hu; Jun-Cheng Shi; Yun-Qing Zhu; Xiao-Ming Mao
Journal:  Ther Clin Risk Manag       Date:  2018-02-26       Impact factor: 2.423

Review 10.  Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies.

Authors:  Muhammad Sajid Hamid Akash; Kanwal Rehman; Fareeha Fiayyaz; Shakila Sabir; Mohsin Khurshid
Journal:  Arch Microbiol       Date:  2020-02-03       Impact factor: 2.667

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.